Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon Cancer
- 1 April 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 3 (4), 438-446
- https://doi.org/10.1158/1940-6207.capr-09-0194
Abstract
Association of chronic inflammation with an increased risk of cancer is well established, but the contributions of innate versus adaptive immunity are not fully delineated. There has furthermore been little consideration of the role played by chronic inflammation–associated antigens, including cancer antigens, and the possibility of using them as vaccines to lower the cancer risk. We studied the human tumor antigen MUC1 which is abnormally expressed in colon cancers and also in inflammatory bowel disease (IBD) that gives rise to colitis-associated colon cancer (CACC). Using our new mouse model of MUC1+ IBD that progresses to CACC, interleukin-10 knockout mice crossed with MUC1 transgenic mice, we show that vaccination against MUC1 delays IBD and prevents progression to CACC. One mechanism is the induction of MUC1-specific adaptive immunity (anti-MUC1 IgG and anti-MUC1 CTL), which seems to eliminate abnormal MUC1+ cells in IBD colons. The other mechanism is the change in the local and the systemic microenvironments. Compared with IBD in vaccinated mice, IBD in control mice is dominated by larger numbers of neutrophils in the colon and myeloid-derived suppressor cells in the spleen, which can compromise adaptive immunity and facilitate tumor growth. This suggests that the tumor-promoting microenvironment of chronic inflammation can be converted to a tumor-inhibiting environment by increasing adaptive immunity against a disease-associated antigen. Cancer Prev Res; 3(4); 438–46. ©2010 AACR.Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory PathwayGastroenterology, 2008
- MUC1 Immunobiology: From Discovery to Clinical ApplicationsAdvances in Immunology, 2004
- MUC1 and the MUCs: A Family of Human Mucins with Impact in Cancer BiologyCritical Reviews in Clinical Laboratory Sciences, 2004
- A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchorProceedings of the National Academy of Sciences, 2003
- Nuclear Magnetic Resonance-Based Dissection of a Glycosyltransferase Specificity for the Mucin MUC1 Tandem RepeatBiochemistry, 2003
- Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal modelsCarcinogenesis: Integrative Cancer Research, 2003
- Inflammation and cancerNature, 2002
- Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in miceVaccine, 2002
- Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic CellsThe Journal of Experimental Medicine, 2002
- A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-Like Receptor 4-Dependent Immunostimulatory Action, and Adjuvant ActivityJournal of Pharmacology and Experimental Therapeutics, 2002